Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: A Comparative Study
Ophthalmologica · 2022 · 245 (5) · 431-438
DOI: 10.1159/000522504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmologica, online erschienen am 25.04.2022. Verfasst von Lakshmi Badrinarayanan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Central Research Instrumentation Facility, Vision Research Foundation, Sankara Nethralaya, Chennai, India. Hauptthemen laut MEDLINE: Ocular Hypertension, Glaucoma, Myopia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Purpose
To compare the incidence, risk factors, treatment, and outcomes associated with intravitreal triamcinolone-acetonide (TA) and dexamethasone-implant (Dex)-induced ocular hypertension (OHT).
Methods
This retrospective study reviewed 1,549 TA and Dex administrations in 1,075 eyes of 897 patients. Intraocular pressure (IOP) values were monitored for a period of 6 months following intravitreal injection(s) and patients were categorized as steroid-responders (SR): IOP≥21 mm Hg, and steroid non-responders (NR): IOP≤20 mm Hg. Glaucoma patients, glaucoma suspects, uveitis, trauma, and less than 1 month of IOP follow-up cases were excluded from the study. The incidence of IOP rise, time and magnitude of IOP rise, and its management procedures were studied. Ocular and systemic associations with OHT incidence were investigated. Statistical analysis was performed using SPSS.23 and p < 0.05 was considered significant.
Result
Twenty-eight percent of TA and 17% of Dex administered eyes developed OHT. Male subjects and elderly people (greater than 40 years of age) are at higher risk for OHT following steroid treatment. A high percentage of IOP rise was observed on day 1 (41%) for TA-SR, and after 1 month (50%) for Dex-SR. IOP rise was found to be more severe (>30 mm Hg) for TA-SR compared to Dex-SR (p = 0.006). 6% TA-SR required trabeculectomy with medically uncontrollable IOP. Myopia is a risk factor for secondary OHT, whereas diabetes mellitus and hypercholesterolemia are protective of it.
Conclusion
Twenty-eight percent of TA and 17% of Dex administrations developed OHT. Early and severe IOP rises were more common in TA than among Dex administrations. Myopia is a risk for Dex-OHT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Research Instrumentation Facility, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
- Shri Bhagwan Mahavir Vitreoretinal Services, Medical Research Foundation, Sankara Nethralaya, Chennai, India.
- Smt. Jadhavbai Nathmal Singhvee Glaucoma Service, Medical Research Foundation, Sankara Nethralaya, Chennai, India.
Zitieren
APA
Badrinarayanan, L., Rishi, P., George, R., Isaac, N., Rishi, E., & Sankara Nethralaya Vitreo-Retinal group (SNVR) (2022). Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: A Comparative Study. Ophthalmologica, 245(5), 431-438. https://doi.org/10.1159/000522504
Vancouver
Badrinarayanan L, Rishi P, George R, Isaac N, Rishi E, Sankara Nethralaya Vitreo-Retinal group (SNVR). Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: A Comparative Study. Ophthalmologica. 2022;245(5):431-438. doi:10.1159/000522504
BibTeX
@article{Badrinarayanan2022,
author = {Badrinarayanan, Lakshmi and Rishi, Pukhraj and George, Ronnie and Isaac, Nancy and Rishi, Ekta and Sankara Nethralaya Vitreo-Retinal group (SNVR), Sankara Nethralaya Vitreo-Retinal group (SNVR)},
title = {Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: A Comparative Study},
journal = {Ophthalmologica},
year = {2022},
volume = {245},
number = {5},
pages = {431--438},
doi = {10.1159/000522504}
}
EUVIMED